Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice

Area of Science:

• Oncology
• Genomics
• Personalized Medicine

Background:

• Advanced hepatocellular carcinoma (HCC) lacks established biomarkers for second-line treatment selection post-immunotherapy.
• Comprehensive genomic profiling (CGP) offers potential for guiding treatment decisions in HCC.

Purpose of the Study:

• To evaluate the utility of CGP in informing treatment decisions for patients with advanced HCC.
• To assess the prevalence of actionable genomic alterations and their impact on treatment selection.

Main Methods:

• Retrospective analysis of 52 advanced HCC patients undergoing CGP (tissue-based and blood-based assays).
• Evaluation of CGP impact on clinical treatment selection and correlation of gene alterations with patient characteristics and immunotherapy response.

Main Results:

• TERT, CTNNB1, TP53, ARID1A, and MYC mutations were frequent.
• Actionable genomic alterations were found in 87% of patients, with 65% recommended for targeted treatments.
• Immunotherapy efficacy showed no significant difference based on the mutation status of key genes.

Conclusions:

• Druggable gene alterations identified via CGP provide valuable information for treatment strategies in advanced HCC.
• CGP can guide the selection of second-line targeted therapies following immunotherapy.